
    
      Objective of this study is to investigate of efficacy and safety of recombinant adenoviral
      human p53 Gene (rAd-p53) in treatment of malignant pleural effusion, compared to cisplatin.
      Study design: phase 2, double blinded, randomized, active controlled.Ninety patients with
      malignant pleural effusion, who meet the study inclusion criteria and none of exclusion
      criteria, will be randomized into 3 treatment groups: rAd-p53, cisplatin, and rAd-p53
      combined with cisplatin. The study endpoints are objective response rate, Karnofsky score,
      effusion-free survival, and safety.
    
  